TR199800848A3 - Yükseltilmis in vivo uygunluga sahip bilesimler. - Google Patents

Yükseltilmis in vivo uygunluga sahip bilesimler.

Info

Publication number
TR199800848A3
TR199800848A3 TR1998/00848A TR9800848A TR199800848A3 TR 199800848 A3 TR199800848 A3 TR 199800848A3 TR 1998/00848 A TR1998/00848 A TR 1998/00848A TR 9800848 A TR9800848 A TR 9800848A TR 199800848 A3 TR199800848 A3 TR 199800848A3
Authority
TR
Turkey
Prior art keywords
elevated
compounds
vivo compatibility
compatibility
vivo
Prior art date
Application number
TR1998/00848A
Other languages
English (en)
Other versions
TR199800848A2 (tr
Inventor
Bosslet Klaus
Czech Joerg
Gerken Manfred
Straub Rainer
Blumrich Matthias
Original Assignee
Hoechst Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Aktiengesellschaft filed Critical Hoechst Aktiengesellschaft
Publication of TR199800848A2 publication Critical patent/TR199800848A2/tr
Publication of TR199800848A3 publication Critical patent/TR199800848A3/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
TR1998/00848A 1997-05-15 1998-05-13 Yükseltilmis in vivo uygunluga sahip bilesimler. TR199800848A3 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19720312A DE19720312A1 (de) 1997-05-15 1997-05-15 Zubereitung mit erhöhter in vivo Verträglichkeit

Publications (2)

Publication Number Publication Date
TR199800848A2 TR199800848A2 (tr) 1998-12-21
TR199800848A3 true TR199800848A3 (tr) 1998-12-21

Family

ID=7829495

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1998/00848A TR199800848A3 (tr) 1997-05-15 1998-05-13 Yükseltilmis in vivo uygunluga sahip bilesimler.

Country Status (17)

Country Link
US (1) US6020315A (tr)
EP (1) EP0879605B1 (tr)
JP (1) JP4367798B2 (tr)
KR (1) KR100547923B1 (tr)
CN (1) CN1188134C (tr)
AR (1) AR012694A1 (tr)
AT (1) ATE333899T1 (tr)
AU (1) AU740694B2 (tr)
BR (1) BR9801632A (tr)
CA (1) CA2237450A1 (tr)
CZ (1) CZ149398A3 (tr)
DE (2) DE19720312A1 (tr)
HU (1) HUP9801087A3 (tr)
ID (1) ID20283A (tr)
PL (1) PL193478B1 (tr)
RU (1) RU2234322C2 (tr)
TR (1) TR199800848A3 (tr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT812195E (pt) 1995-02-28 2003-03-31 Aventis Pharma Inc Composicao farmaceutica para compostos de piperidinoalcanol
ATE218556T1 (de) 1995-11-17 2002-06-15 Biotechnolog Forschung Gmbh Epothilon-derivate und deren herstellung
DK1367057T3 (da) 1996-11-18 2009-01-19 Biotechnolog Forschung Gmbh Epothiloner E og F
CA2273083C (en) 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
PL192079B1 (pl) * 1997-08-26 2006-08-31 Aventis Pharmaceuticals Kompozycja farmaceutyczna w postaci dwuwarstwowej tabletki
US6320045B1 (en) 1997-12-04 2001-11-20 Bristol-Myers Squibb Company Process for the reduction of oxiranyl epothilones to olefinic epothilones
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6399638B1 (en) 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6780620B1 (en) 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
NZ513629A (en) 1999-02-22 2004-01-30 Bristol Myers Squibb Co C-21 modified epothilones
US6291684B1 (en) 1999-03-29 2001-09-18 Bristol-Myers Squibb Company Process for the preparation of aziridinyl epothilones from oxiranyl epothilones
ATE301129T1 (de) 1999-05-04 2005-08-15 Strakan Int Ltd Androgen glykoside und die androgenische aktivität davon
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
GB2355007A (en) * 1999-10-08 2001-04-11 Michael Francis Holick Tamoxifen analogue glycosides and use thereof
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
CA2307278A1 (en) * 2000-04-28 2001-10-28 University Of British Columbia Use of n-heterocyclic substituted salicylic acids for inhibition of cellular uptake of cystine
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
CN1469735A (zh) * 2000-10-16 2004-01-21 ����˹��ҩ�﹫˾ 米托蒽醌的脂质体制剂
CZ20032022A3 (cs) 2001-01-25 2004-04-14 Bristol-Myers Squibb Company Parenterální prostředek obsahující epothilonová analoga
PT1353668E (pt) 2001-01-25 2008-06-30 Bristol Myers Squibb Co Processos de preparação de substâncias farmacêutica contendo substâncias análogas à epotilona para o tratamento de cancro
WO2002058699A1 (en) 2001-01-25 2002-08-01 Bristol-Myers Squibb Company Pharmaceutical forms of epothilones for oral administration
CN1610549A (zh) 2001-02-20 2005-04-27 布里斯托尔-迈尔斯斯奎布公司 用于治疗难治肿瘤的埃坡霉素衍生物
EE200300396A (et) 2001-02-20 2003-12-15 Bristol-Myers Squibb Company Epotilooni derivaatide kasutamine refraktaarsete kasvajate raviks
EE05417B1 (et) 2001-03-14 2011-06-15 Bristol-Myers Squibb Company Epotilooni analoogide ja kemoterapeutikumide kombinatsiooni kasutamine teraapias
JP2004532888A (ja) 2001-06-01 2004-10-28 ブリストル−マイヤーズ　スクイブ　カンパニー エポチロン誘導体
ATE371458T1 (de) * 2001-08-14 2007-09-15 Valderm Aps Behandlung von hyperproliferativen zuständen von körperoberflächen
US20030194421A1 (en) * 2001-12-28 2003-10-16 Angiotech Pharmaceuticals, Inc. Treatment of uveitis
AU2003218107A1 (en) 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
TW200403994A (en) 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
WO2003105828A1 (en) 2002-06-14 2003-12-24 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
DK1767535T3 (da) 2002-08-23 2010-04-12 Sloan Kettering Inst Cancer Syntese af epothiloner, mellemprodukter deraf, analoge og deres anvendelse
KR20050053681A (ko) 2002-09-23 2005-06-08 브리스톨-마이어스 스큅 컴퍼니 에포틸론 ｂ의 제조, 분리 및 정제 방법, 및 에포틸론 ｂ의ｘ-선 결정 구조
ZA200507752B (en) * 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
EP1896040B1 (en) 2005-06-29 2012-08-01 Threshold Pharmaceuticals, Inc. Phosphoramidate alkylator prodrugs
US9737640B2 (en) * 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414526B2 (en) * 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
EP2114157B1 (en) * 2006-12-26 2021-05-26 ImmunoGenesis, Inc. Phosphoramidate alkylator prodrug for the treatment of cancer
US20090118031A1 (en) * 2007-11-01 2009-05-07 Qualizza Gregory K Shaft Structure with Configurable Bending Profile
WO2013026454A1 (en) * 2011-08-22 2013-02-28 Valderm Aps Treatment of clinical conditions with anthracyclines
GB201414806D0 (en) * 2014-08-20 2014-10-01 Ucl Business Plc Cyclosporin conjugates

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ225599A (en) * 1987-08-04 1991-09-25 Bristol Myers Co Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells
FR2676058B1 (fr) * 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
EP0647450A1 (en) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
DE4417865A1 (de) * 1994-05-20 1995-11-23 Behringwerke Ag Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie
ATE278700T1 (de) * 1995-06-27 2004-10-15 Pharmachemie Bv Anthracyclin prodrugs, verfahren zu deren herstellung und deren verwendung in der selektiven chemotherapie
ES2257756T3 (es) * 1996-03-12 2006-08-01 Sanofi-Aventis Deutschland Gmbh Nuevos profarmacos para la terapia de tumores y enfermedades inflamatorias.

Also Published As

Publication number Publication date
AU740694B2 (en) 2001-11-15
ATE333899T1 (de) 2006-08-15
RU2234322C2 (ru) 2004-08-20
JP4367798B2 (ja) 2009-11-18
PL193478B1 (pl) 2007-02-28
KR100547923B1 (ko) 2006-04-12
EP0879605B1 (de) 2006-07-26
AU6600598A (en) 1998-11-19
PL326336A1 (en) 1998-11-23
HUP9801087A2 (hu) 1998-12-28
CA2237450A1 (en) 1998-11-15
CZ149398A3 (cs) 1998-12-16
EP0879605A2 (de) 1998-11-25
TR199800848A2 (tr) 1998-12-21
HUP9801087A3 (en) 1999-05-28
BR9801632A (pt) 1999-06-29
CN1188134C (zh) 2005-02-09
HU9801087D0 (en) 1998-07-28
ID20283A (id) 1998-11-19
EP0879605A3 (de) 1998-12-02
KR19980087239A (ko) 1998-12-05
DE59813653D1 (de) 2006-09-07
JPH1129497A (ja) 1999-02-02
AR012694A1 (es) 2000-11-08
US6020315A (en) 2000-02-01
CN1199613A (zh) 1998-11-25
DE19720312A1 (de) 1998-11-19

Similar Documents

Publication Publication Date Title
TR199800848A3 (tr) Yükseltilmis in vivo uygunluga sahip bilesimler.
DK0954547T3 (da) Epoxy-polysiloxanpolymer-præparat
PT996701E (pt) Polialquilenoiminas alcoxiladas compativeis com lixivia
NO2006014I1 (no) Insulin glulisin
DE69838231D1 (de) Kanülenanordnung
ID20807A (id) Asam sulfonilaminokarboksilat
NL1010861A1 (nl) Aandrijving.
EE9800340A (et) Pump
NL1012971A1 (nl) Aandrijving.
NL1010859A1 (nl) Aandrijving.
DE59809902D1 (de) Mehrkammerpumpe
DE59803554D1 (de) Förderpumpe
IT243482Y1 (it) Sfarinatore intensivo.
ES1039369Y (es) Estanteria.
FI103524B (fi) Liitosjärjestely
ES1036909Y (es) Pupitre infantil.
ES1040213Y (es) Mondadientes triangular plano.
TR199901284A3 (tr) Ester bilesimleri.
ES1040856Y (es) Envase.
DE29709908U1 (de) Kombinationsregal
DE59710244D1 (de) Zahnradpumpe
ES1038361Y (es) Pendiente luminoso.
FI971041A0 (fi) Sjaelvnedstigande ledstege
ES1040131Y (es) Atril simplificado.
ES1037151Y (es) Horma.